Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy

BMJ Case Reports

Volumn , Issue , 2014, Pages

  Lee, Samantha C ^a   Feenstra, John ^a,b   Georghiou, Paul R ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WESLEY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; HYDROXYUREA; RUXOLITINIB;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; FEVER; HUMAN; LOW DRUG DOSE; MALE; MYELOFIBROSIS; NEUTROPHILIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTOSIS; TRANSBRONCHIAL BIOPSY;

EID: 84901926662     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2014-204950     Document Type: Article

References (10)

1. Ganetsky A. Ruxolitinib: a new treatment option for myelofibrosis. Pharmacotherapy 2013;33:84-92.
2. Massa M, Rosti V, Campanelli R, et al. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia 2014;28:449-51.
3. Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013;122:1192-202.
4. Goldberg R, Reichel E, Oshry L. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013;369:681-3.
5. Wysham N, Sullivan D, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2, inhibitor. Chest 2013;143:1478-9.
6. Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012;5:552-3.
7. Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013;369:197-8.
8. Stansfield LC, Begna K, Tosh P, et al. Mucormycosis in a patient treated with ruxolitinib. Blood 2014; e-letter published 31 January. http://bloodjournal.hematologylibrary.org/letters (accessed 6 Mar 2014).
9. Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014:28:225-7.
10. Tong LX, Jackson J, Kerstetter J, et al. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol 2014;70:e59-60.